Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acetylcysteine/Doxofylline in Moderate-Severe COPD
NCT03388853Phase 4Completed
- Sponsor
- Neutec Group
- Start
- Feb 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Acetylcysteine/Doxofylline with Placebo (2 arms). Primary endpoint: Breathlessness, Cough, and Sputum Scale at 4 weeks. Started Feb 2018; status: completed.
02
Drugs
acetylcysteinedoxofylline
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03388853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03388853.